Conference Call/Webcast to be Held Tuesday, August 7, 2012 at 10:00 AM EDT
CEDAR KNOLLS, N.J., Aug. 7, 2012 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) (the "Company") today announced its financial results for the quarter and year to date ended June 30, 2012. The Company will host a conference call this morning at 10:00 AM EDT to discuss these results.
The live webcast of the conference call can be accessed through the company's web site at: www.emisphere.com. The live conference call dial-in number is: 1-888-857-6932 (United States and Canada) or 1-719-457-1529 (International). In addition, an archive of the webcast can be accessed through the same link and an audio replay of the call will be available beginning at 1:00 PM EDT on August 7, 2012 through 1:00 AM EDT on August 23, 2012 by calling 1-888-203-1112 (United States and Canada) or 1-719-457-0820 (International). The conference replay PIN is 7575840.
SECOND QUARTER 2012 FINANCIAL RESULTS
The Company reported net income of $2.8 million, or $0.05 per basic and diluted share, for the three months ended June 30, 2012, compared to net income of $1.8 million, or $0.04 per basic and $0.03 per diluted share for same period last year.
An operating loss of $1.4 million was reported for the three months ended June 30, 2012, compared to an operating loss of $2.2 million in same period last year. Total operating expenses were $1.4 million for the three months ended June 30, 2012, compared to $2.2 million for the same period last year. Total operating expenses include research and development costs of $0.3 million and general and administrative expenses of $1.1 million, compared to $0.6 million and $1.6 million, respectively, for the same period last year. Other non-operating income was $4.2 million for the three months ended June 30, 2012, compared to other non-operating income of $4.1 million for the same period last year, an increase of $0.1 million, due primarily to a $0.5 million increase in the change in fair value of derivative instruments, offset by a net $0.4 million increase in interest expense.
YEAR TO DATE FINANCIAL RESULTS
The Company reported net income of $2.0 million, or $0.03 per basic and diluted share for the six months ended June 30, 2012, compared to net income of $12.8 million, or $0.25 per basic and $0.22 per diluted share for the six months ended June 30, 2011.
An operating loss of $3.2 million was reported for the six months ended June 30, 2012, compared to $4.3 million for the same period last year. Total operating expenses were $3.2 million for the six months ended June 30, 2012, a decrease of approximately $1.1 million, or 25% compared to $4.3 million for the same period last year. Total operating expenses include research and development costs of $0.8 million and general and administrative expenses of $2.4 million, compared to $1.1 million and $3.1 million respectively, for the same period last year. The prior year period also included depreciation and amortization expense of $0.1 million.
Other non-operating income was $5.2 million for the six months ended June 30, 2012, compared to other non-operating income of $17.1 million for the same period last year, a decrease of $11.9 million, due primarily to a $12.7 million decrease in the change in fair value of derivative instruments and a $0.7 million increase in interest expense, offset by a $1.5 million increase in other income.
The Company reported that cash, cash equivalents and restricted cash held as of June 30, 2012 was $1.6 million, a net decrease of approximately $1.7 million from December 31, 2011. The Company reduced its operating expenditures by approximately 30%, year to date, to improve operating efficiency and extend its cash runway. Consequently, we anticipate our current cash balance will enable us to continue operations through September 26, 2012, the date on which the 11% senior secured convertible notes (the "MHR Convertible Notes") held by MHR Fund Management, LLC and its affiliates (collectively, "MHR") come due, or earlier if unforeseen events or circumstances arise that negatively affect our liquidity.
As of June 30, 2012, the book value of the MHR Convertible Notes outstanding including principal, interest and discount for warrant purchase option and embedded conversion features is $28.8 million. The amount payable at maturity will be approximately $30.5 million. The MHR Convertible Notes are collateralized by a first priority lien in favor of MHR on substantially all of our assets. The Company is considering a variety of alternatives to address the upcoming maturity of the MHR Convertible Notes.
During 2011 and through the first half of 2012, the Company faced formidable challenges, yet continued to focus on efforts to apply the Eligen® Technology and realize its value by developing profitable commercial applications. Notwithstanding the Company's optimism for the technology, Emisphere was adversely affected by the announcement by its research collaboration partner Novartis Pharma AG ("Novartis") of the termination of its oral human growth hormone, osteoarthritis, and osteoporosis programs involving Emisphere's Eligen® Technology. Emisphere has requested additional information from Novartis to further analyze and evaluate the data from three studies in osteoporosis and osteoarthritis conducted by Novartis and its development partner in order to understand the results and determine next steps.
Emisphere's pipeline includes a broad range of product candidates in different stages of development.
Novo Nordisk A/S ("Novo Nordisk") is using Emisphere's Eligen® Technology to develop and commercialize oral formulations of Novo Nordisk's insulins and GLP-1 receptor agonists, with a potential GLP-1 drug currently undergoing Phase I clinical trials. The first Phase I trial investigated the safety, tolerability and bioavailability in healthy volunteers and was completed in May 2010. Novo Nordisk also conducted a multiple-dose Phase I trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics in healthy male subjects which was completed in July 2011.
The Company has developed an oral formulation of Eligen® B12 (1000 mcg) for use by B12 deficient individuals. On August 5, 2011 we received notice from the U. S. Patent Office that the U.S. patent application directed to the oral Eligen® B12 formulation was allowed. This new patent provides intellectual property protection for Eligen® B12 in the U.S. through approximately 2029. Currently, we are evaluating the results of our clinical trials and market research and exploring alternative development and commercialization options with the purpose of maximizing the commercial and health benefits potential of our Eligen® B12 asset.
The Company is continuing with a number of pre-clinical programs in collaboration with other companies, as well as projects on its own, using the Eligen® Technology to improve the oral absorption of selected molecules.
About Emisphere Technologies, Inc.
Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds, medical foods and dietary supplements using its Eligen® Technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The Eligen® Technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The Company's website is: www.emisphere.com.
The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates, the sufficiency of Emisphere's cash and other capital resources and its ability to obtain additional financing to meet its capital needs) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, Emisphere's ability to fund such efforts with or without partners, and other risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K for the fiscal year ended December 31, 2011 (file no. 000-17758) filed on March 21, 2012, the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012, filed on May 9, 2012, and the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2012, to be filed on or about the date hereof.
EMISPHERE TECHNOLOGIES, INC.
CONDENSED STATEMENT OF OPERATIONS
For the three and six months ended June 30, 2012 and 2011
(in thousands, except share and per share data)
For the three months ended June 30,
For the six months ended June 30,
Costs and expenses:
Research and development
General and administrative
Depreciation and amortization
Total costs and expenses
Other non-operating income (expense):
Change in fair value of derivative instruments
Total other non-operating income (expense)
Net income per share, basic
Net income per share, diluted
Weighted average shares outstanding, basic
Weighted average shares outstanding, diluted
EMISPHERE TECHNOLOGIES, INC.
CONDENSED BALANCE SHEETS
June 30, 2012 and December 31, 2011
(in thousands, except share and per share data)
June 30, 2012
December 31, 2011
Cash and cash equivalents
Accounts receivable, net
Prepaid expenses and other current assets
Total current assets
Equipment and leasehold improvements, net
Liabilities and Stockholders' Deficit:
Accounts payable and accrued expenses
Notes payable related party, including accrued interest and net of related discount
Other current liabilities
Total current liabilities
Deferred lease liability and other liabilities
Preferred stock, $.01 par value; authorized 2,000,000 shares as of June 30, 2012; and 1,000,000 authorized as of December 31, 2011; none issued and outstanding
Common stock, $.01 par value; authorized 200,000,000 shares as of June 30, 2012 and 100,000,000 authorized as of December 31, 2011; issued 60,977,210 shares (60,687,478 outstanding) as of June 30, 2012 and December 31, 2011
Common stock held in treasury, at cost; 289,732 shares